Kiniksa Pharmaceuticals International, plc (KNSA) fair value analysis

Nasdaq · Updated 2026-09-07

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company that develops and commercializes medicines to treat inflammatory and autoimmune diseases. The company operates internationally with operations spanning the United States and other markets.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, KNSA is trading at within about 10% of estimated fair value.

KNSA currently ranks #58 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $73.41
Sector: Healthcare
12-month range: $37.47–$73.41

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: Low
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range

What our data shows for KNSA

Our model validated 7 trailing price-to-earnings windows for KNSA, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $37.47–$73.41.
The 14-day relative strength index sits at a neutral 47.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for KNSA
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent KNSA news

TickrTrends' derived news-sentiment signal for KNSA is currently mixed, computed from recent coverage.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript (insidermonkey.com, 2026-02-25)
TickrTrends take: # KNSA Stock Research Kiniksa Pharmaceuticals operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends analysis. As the company reported its Q4 2025 results, investors focused on valuation should monitor whether management commentary on revenue trends, pipeline progress, and cash burn rates supports the fair value designation or signals a need for valuation adjustment. The earnings call provides an opportunity to evaluate whether the company's financial performance and strategic positioning justify its current market valuation relative to peers in the pharmaceutical industry.
Kiniksa Pharmaceuticals, Ltd. Q4 2025 Earnings Call Summary (finance.yahoo.com, 2026-02-25)
TickrTrends take: Kiniksa Pharmaceuticals operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends analysis. For valuation-focused readers, Q4 2025 earnings results will be important to monitor whether the company's financial performance supports maintaining its current valuation level or whether metrics such as revenue growth, cash burn, or pipeline progress warrant a reassessment. Given the fair value designation, any significant divergence between reported results and market expectations could indicate whether the stock is appropriately priced relative to its fundamentals.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2025 Earnings Call Transcript (insidermonkey.com, 2025-11-03)
TickrTrends take: KNSA operates in the Healthcare sector where earnings performance directly influences valuation multiples and investor confidence in pipeline execution. With TickrTrends currently assessing KNSA as fairly valued, the Q3 2025 earnings call provides an opportunity for investors to evaluate whether the company's revenue trends, cash burn rate, and clinical trial progress support that valuation level or suggest a reassessment is warranted. Valuation-focused readers should monitor management's commentary on product adoption rates and R&D spending efficiency, as these metrics typically drive rerating in pharmaceutical stocks trading near fair value.

What people are saying

Follow the KNSA conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is KNSA stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), KNSA is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is KNSA's TickrTrends verdict?

KNSA's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does KNSA compare to other Healthcare stocks?

KNSA ranks #58 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is KNSA overbought or oversold?

KNSA's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

KNSA vs A · KNSA vs BDX · KNSA vs DHR · KNSA vs ENSG · KNSA vs INVA